| INTRODUCTION
The patatin-like phospholipase domain containing 3 (PNPLA3) protein is a lipase with activity towards triglycerides in hepatocytes 1 as well as retinyl esters in hepatic stellate cells 2 and experimental studies have shown that p.I148M substitution leads to a loss of function. 3 The PNPLA3 rs738409 G allele encoding the I148M variant (Human Genom Variation Society Nomenclature: NC_000022.10:
g.44324727C>G) 4 has been linked to non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) 1, 4 and disease severity, 5 alcoholic liver disease (ALD)-induced cirrhosis [6] [7] [8] [9] and outcome after severe alcoholic hepatitis. 10 Moreover, it has been linked to hepatic steatosis/liver fibrosis in hepatitis C virus-monoinfected 11 and HIV/hepatitis C virus-coinfected 12 patients, although its effects in viral hepatitis were less consistent when compared to patients with fatty liver disease. 13 Finally, the PNPLA3 G allele has repeatedly been found to be associated with hepatocellular carcinoma (HCC) development. 1, 13 Recent data indicates that the PNPLA3 G allele potentiates the proinflammatory and profibrogenic features of hepatic stellate cells. 14, 15 Hepatic stellate cells are not only a key player in liver fibrogenesis but also play an essential role in the perpetuation of portal hypertension. Due to its impact on hepatic stellate cell activation, the PNPLA3 G allele might promote liver disease progression, even beyond the initiation of liver fibrosis/portal hypertension, and thus, have prognostic implications in advanced chronic liver disease (ie in patients who have already developed portal hypertension).
We aimed to investigate the impact of the PNPLA3 G allele on (liver-related) mortality in our thoroughly characterised cohort of 372 patients who had already developed portal hypertension due to ALD/ NAFLD or viral hepatitis (longitudinal study). To examine the underlying mechanism, we assessed whether PNPLA3 genotype is linked to hepatic steatosis, as evaluated by controlled attenuation parameter in a similar cohort of 153 consecutive patients (cross-sectional study).
| PATIENTS AND METHODS

| Study population
To investigate the impact of the PNPLA3 G allele on mortality,
we performed a retrospective analysis in 372 prospectively characterised patients with portal hypertension (hepatic venous pressure gradient [HVPG] ≥6 mm Hg) diagnosed at the Medical University of Vienna through 2013 (cohort I; longitudinal study). 16 Since the effect of PNPLA3 might vary throughout different aetiologies, only patients with ALD/NAFLD-or viral hepatitis-induced portal hypertension were included. Aetiology was determined based on medical history at the time of HVPG measurement. 
| Definition of hepatic decompensation
Patients' medical records were reviewed for the following events which defined (further) hepatic decompensation: Requirement of paracentesis, admission for grade 3/4 hepatic encephalopathy, variceal bleeding and liver-related death.
| Liver stiffness and controlled attenuation parameter measurement
Measurement of controlled attenuation parameter was performed after an overnight fast by transient elastography using a FibroScan 502 Touch (Echosens, Paris, France). 20 Hepatic steatosis was graded according to cut-offs derived from a recent meta-analysis based on individual patient data 21 : ≥248 dB 9 m À1 for ≥S1, ≥268 dB 9 m
À1
for ≥S2 and ≥280 dB 9 m À1 for S3. Variables that showed differences between PNPLA3 genotypes or those which we considered highly relevant for the endpoint of interest were included as covariates in multivariate analyses.
| Statistical analyses
A P ≤0.05 was considered statistically significant.
| Ethics
The study was conducted in accordance with the Declaration of PNPLA3 G allele carriers were more commonly male, when compared to C/C patients (Table S1 ). Moreover, ALD/NAFLD was overrepresented among patients harbouring a PNPLA3 G allele.
PNPLA3 G allele carriers also showed more severe liver disease, as indicated by higher HVPG and MELD scores as well as lower serum albumin levels. A comparison between PNPLA3 G/G and non-G/G patients yielded similar differences (Table 1) . Stratifying patients by aetiology (viral hepatitis and fatty liver disease), we observed trends towards a higher proportion of males and higher HVPG values among PNPLA3 G/G patients of both aetiologies (Table 1) .
| Impact of PNPLA3 genotype on transplantfree mortality in cohort I
Patients were followed for a median of 27.4 (37.6) months. Twentyfive (7%) patients underwent liver transplantation, while 104 patients
While transplant-free survival was similar between PNPLA3 C/C and C/G patients (at 5 years: 72% vs 66% P = 0.635; Figure S1 ), we observed substantially impaired transplant-free survival in G/G patients (at 5 years: 47%; P = 0.026 vs C/C and P = 0.003 vs C/G). Thus, for further analyses, patients were grouped into PNPLA3 G/G and non-G/G.
Overall, PNPLA3 G/G genotype (adjusted hazard ratio [aHR]:
1.42, 95% confidence interval [95% CI]: 0.879-2.3; P = 0.151) tended to increase transplant-free mortality in an analysis adjusted for age, sex, aetiology, HVPG, MELD and serum albumin levels (Table 2 and Figure 1 ).
Since previous studies on the impact of PNPLA3 on liver disease severity observed more consistent effects in fatty liver disease, as compared to viral hepatitis, we analysed these groups separately (Table 2 To further investigate the impact of PNPLA3 G/G genotype on mortality, we conducted a competing risk regression analysis adjusted for age, sex, aetiology, HVPG, MELD, and serum albumin levels, considering liver transplantation as a competing risk ( (Table 3 and Figure 2 ).
In an analysis considering liver transplantation and nonliverrelated death as competing risks, PNPLA3 G/G genotype was associated with a twofold increase in risk of hepatic decompensation
(aSHR: 2.1, 95% CI: 1.1-4; P = 0.024), after adjusting for potential confounding factors (Table 3 and Figure 2 ). 
T A B L E 1 Comparison of patient characteristics between patatin-like phospholipase domain-containing protein 3 (PNPLA3) G/G and non-G/G in A the overall cohort, B among patients with viral hepatitis and C among patients with alcoholic (ALD)/nonalcoholic fatty liver disease (NAFLD) (cohort I)
A
| DISCUSSION
Previous studies established firm associations between the PNPLA3 G allele and NAFLD/NASH 4 and disease severity. 5 More recently, the PNPLA3 G allele has also been linked to ALD-induced cirrhosis. [6] [7] [8] [9] As opposed to this, its effects in viral hepatitis were less consistent. 13 We observed an overrepresentation of ALD/NAFLD among carriers of the PNPLA3 G allele, supporting its particular relevance in these aetiologies (cohort I; trend in cohort II). This is in line with a study by Fatelli et al 23 Considering liver transplantation and nonliver-related death as competing risks. SHR, subdistribution hazard ratio; 95% CI, 95% confidence interval; HVPG, hepatic venous pressure gradient; MELD, model for end-stage liver disease.
information on the prognostic impact of the PNPLA3 G allele in patients who have already developed portal hypertension. F I G U R E 2 A, Liver-related mortality and B, hepatic decompensation in fatty liver disease patients with the patatin-like phospholipase domain-containing protein 3 (PNPLA3) G/G genotype, or without, considering liver transplantation and nonliver-related death as competing risks (cohort I). aSHR, adjusted subdistribution hazard ratio; 95% CI, 95% confidence interval patients who were abstinent from drinking. However, the proportion of patients with underlying advanced chronic liver disease included in the STOPAH trial remains unclear. In our study, harbouring the PNPLA3 G/G genotype doubled the mortality risk of patients with portal hypertension due to (predominantly alcoholic) fatty liver disease (cohort I). Interestingly, this effect was also observed in the subgroup of patients with clinically significant portal hypertension, in whom splanchnic vasodilatation/hyperdynamic circulation, rather than "intrahepatic" factors such as PNPLA3, is considered as the main determinant of portal pressure. 28, 29 However, this paradigm has already been challenged by improvements in portal pressure after achieving sustained virologic response to hepatitis C treatments, which were observed throughout all strata of portal hypertension severity. [30] [31] [32] Although the numerically increased rates of HCC development among PNPLA3 G/G patients might have contributed to the observed association between PNPLA3 G/G and mortality (cohort I), considering the small number of patients who were diagnosed with HCC, differences in (liver-related) mortality cannot solely explained by HCC development.
To further explore the mechanism by which the PNPLA3 G/G genotype might promote hepatic decompensation and increase (liver-related) mortality in patients who have already developed portal hypertension, we analysed controlled attenuation parameter (possibly indicating hepatic steatosis) in a similar patient population (cohort II).
Notably, PNPLA3 genotype had no impact on controlled attenuation parameter, which would suggest that its effect on hepatic steatosis is less pronounced in patients who have already progressed to advanced chronic liver disease. Importantly, previous studies have demonstrated the disappearance of hepatic steatosis with liver fibrosis progression in NAFLD patients (ie "burnt-out NASH"), 33 a phenomenon which might also occur in ALD and might have attenuated the effect of PNPLA3 genotype on controlled attenuation parameter in our study, although the proportion of patients with controlled attenuation parameter values indicative of hepatic steatosis was still 48%. Moreover, there is only limited data on the performance of controlled attenuation parameter for diagnosing hepatic steatosis in patients with advanced chronic liver disease; however, it was not impacted by the presence of cirrhosis in a recent meta-analysis of individual patient data. 21 In addition, its diagnostic performance seemed to be similar among ALD patients with advanced liver fibrosis or without. 34 Considering these potential limitations as well as the small sample size of cohort II, our findings should be interpreted with caution and require confirmation.
Until recently, the impact of PNPLA3 genotype on hepatic lipid metabolism, and thus, hepatic steatosis, was considered as the primary explanation for its association with liver disease and its progression. 3 Notably, Pingitore et al 14 The main limitation of this study is its retrospective design; however, patients were prospectively characterised at the time of HVPG measurement. Moreover, the number of patients with fatty liver disease included in cohort I was limited and our study did not include a validation cohort. Aetiology was determined based on medical history and the diagnostic work up did not include a liver biopsy in most cases. In addition, alcohol abstinence was not systematically assessed. Finally, the impact of PNPLA3 genotype on clinical events and controlled attenuation parameter was not investigated in the same patient cohort, since controlled attenuation parameter became available in 2014 at our institution. However, inclusion criteria and study setting were exactly the same for both cohorts, which resulted in similar patient characteristics.
Analysing clinical events in patients evaluated before 2014 allowed for a longer follow-up duration, a higher number of clinical events, and thus, more robust estimates of the impact of PNPLA3 genotype.
In summary, PNPLA3 G/G genotype seems to double the risks of liver-related morbidity and mortality in patients with portal hypertension due to fatty liver disease, even after the development of clinically significant portal hypertension. Further studies are warranted to investigate potential underlying pathophysiological mechanisms unrelated to hepatic steatosis.
AUTHORSHIP
Guarantor of the article: Arnulf Ferlitsch. 
